Author

Millie Long

DURABILITY OF OZANIMOD RESPONSE BY BASELINE ENDOSCOPIC DISEASE ACTIVITY IN ADVANCED THERAPY–NAIVE PATIENTS WITH ULCERATIVE COLITIS UNCONTROLLED ON CONVENTIONAL THERAPIES: INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION
DURABILITY OF OZANIMOD RESPONSE BY BASELINE ENDOSCOPIC DISEASE ACTIVITY IN ADVANCED THERAPY–NAIVE PATIENTS WITH ULCERATIVE COLITIS UNCONTROLLED ON CONVENTIONAL THERAPIES: INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION

Millie Long  et al.

EFFICACY OF OZANIMOD AS AN INDUCTION THERAPY IN ADVANCED THERAPY–NAIVE ULCERATIVE COLITIS PATIENTS SUBOPTIMALLY CONTROLLED ON CONVENTIONAL TREATMENTS
EFFICACY OF OZANIMOD AS AN INDUCTION THERAPY IN ADVANCED THERAPY–NAIVE ULCERATIVE COLITIS PATIENTS SUBOPTIMALLY CONTROLLED ON CONVENTIONAL TREATMENTS

Millie Long  et al.

EFFICACY OF UPADACITINIB DOSE ESCALATION IN A PHASE 3 LONG-TERM EXTENSION ULCERATIVE COLITIS STUDY
EFFICACY OF UPADACITINIB DOSE ESCALATION IN A PHASE 3 LONG-TERM EXTENSION ULCERATIVE COLITIS STUDY

Millie Long  et al.

SAFETY OF USTEKINUMAB ACROSS APPROVED ADULT INDICATIONS: POOLED SAFETY ANALYSIS IN CROHN’S DISEASE, ULCERATIVE COLITIS, PSORIASIS, AND PSORIATIC ARTHRITIS THROUGH UP TO 5 YEARS
SAFETY OF USTEKINUMAB ACROSS APPROVED ADULT INDICATIONS: POOLED SAFETY ANALYSIS IN CROHN’S DISEASE, ULCERATIVE COLITIS, PSORIASIS, AND PSORIATIC ARTHRITIS THROUGH UP TO 5 YEARS

Millie Long  et al.

OZANIMOD IS AN EFFECTIVE ORAL TREATMENT FOR PATIENTS WITH ULCERATIVE COLITIS REGARDLESS OF MODERATE OR SEVERE ENDOSCOPIC DISEASE ACTIVITY: A POST HOC ANALYSIS OF TRUE NORTH
OZANIMOD IS AN EFFECTIVE ORAL TREATMENT FOR PATIENTS WITH ULCERATIVE COLITIS REGARDLESS OF MODERATE OR SEVERE ENDOSCOPIC DISEASE ACTIVITY: A POST HOC ANALYSIS OF TRUE NORTH

Millie Long  et al.

EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL
EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL

Millie Long  et al.

SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL
SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL

Millie Long  et al.

HISTOLOGICAL INFLAMMATION PREDICTS LOSS OF REMISSION AMONG CROHN’S PATIENTS WITH ENDOSCOPIC REMISSION: A US COHORT ANALYSIS
HISTOLOGICAL INFLAMMATION PREDICTS LOSS OF REMISSION AMONG CROHN’S PATIENTS WITH ENDOSCOPIC REMISSION: A US COHORT ANALYSIS

Millie Long  et al.

PRESENCE OF RISK FACTORS ASSOCIATED WITH COLECTOMY AMONG PATIENTS WITH COLECTOMY IN THE TOFACITINIB OCTAVE ULCERATIVE COLITIS CLINICAL PROGRAMME
PRESENCE OF RISK FACTORS ASSOCIATED WITH COLECTOMY AMONG PATIENTS WITH COLECTOMY IN THE TOFACITINIB OCTAVE ULCERATIVE COLITIS CLINICAL PROGRAMME

Millie Long  et al.

OZANIMOD AS A MAINTENANCE THERAPY IN ADVANCED THERAPY–NAIVE ULCERATIVE COLITIS PATIENTS WITH MODERATE VS SEVERE ENDOSCOPIC DISEASE
OZANIMOD AS A MAINTENANCE THERAPY IN ADVANCED THERAPY–NAIVE ULCERATIVE COLITIS PATIENTS WITH MODERATE VS SEVERE ENDOSCOPIC DISEASE

Millie Long  et al.

Item 1 - 10 / 10
1